Comparison of mucosal and systemic humoral immune responses after transcutaneous and oral immunization strategies

Vaccine

Volumn 20, Issue 21-22, 2002, Pages 2720-2726

  John, Manohar ^a,b   Bridges, Emily A ^a   Miller, Andy O ^a   Calderwood, Stephen B ^a,b   Ryan, Edward T ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Immunization; Oral; Transcutaneous

Indexed keywords

CHOLERA TOXIN; CHOLERA TOXIN B SUBUNIT; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIVE VACCINE; BACTERIAL VACCINE; BACTERIUM ANTIBODY; CHOLERA VACCINE; RECOMBINANT VACCINE;

ANIMAL EXPERIMENT; ARTICLE; BILE LEVEL; BLOOD LEVEL; CHOLERA; CONTROLLED STUDY; EXPRESSION VECTOR; FECES LEVEL; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; INTERMETHOD COMPARISON; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; VIBRIO CHOLERAE; ANIMAL; ANIMAL MODEL; ANTIBODY PRODUCTION; BLOOD; COMPARATIVE STUDY; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANIMAL; ANTIBODIES, BACTERIAL; ANTIBODY FORMATION; BACTERIAL VACCINES; CHOLERA VACCINES; COMPARATIVE STUDY; FEMALE; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MODELS, ANIMAL; SUPPORT, U.S. GOV'T, P.H.S.; VACCINES, SYNTHETIC; VIBRIO CHOLERAE; ANIMALS;

EID: 0037150474     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00208-6     Document Type: Article

References (33)

1. Transcutaneous immunization: A human vaccine delivery strategy using a patch
2. Skin immunization made possible by cholera toxin
3. Induction of systemic immune responses in sheep by topical application of cholera toxin to skin
4. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge
5. Transcutaneous immunization of domestic animals: Opportunities and challenges
6. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants
7. Transcutaneous immunization: T cell responses and boosting of existing immunity
8. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants
9. Transcutaneous immunization induces mucosal and systemic immunity: A potent method for targeting immunity to the female reproductive tract
10. Duration of infection-derived immunity to cholera
11. Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferon-gamma production and evokes local immunological memory
12. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR
13. Cholera toxin genes: Nucleotide sequence, deletion analysis and vaccine development
14. CtxB genetic element encodes a site-specific recombination system and an intestinal colonization factor [published erratum appears in Proc. Natl. Acad. Sci. USA 1993 Sep 1;90(17):8302]
15. Initial clinical studies of CVD112 Vibrio cholerae O139 live oral vaccine: Safety and efficacy against experimental challenge
16. Emergence of a new cholera pandemic: Molecular analysis of virulence determinants in Vibrio cholerae O139 and development of a live vaccine prototype
17. Use of the Vibrio cholerae irgA gene as a locus for insertion and expression of heterologous antigens in cholera vaccine strains
18. Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cholerae vector strain
19. Protective immunity to Shiga-like toxin I following oral immunization with Shiga-like toxin I B-subunit-producing Vibrio cholerae CVD 103-HgR
20. Oral immunization with attenuated vaccine strains of Vibrio cholerae expressing a dodecapeptide repeat of the serine-rich Entamoeba histolytica protein fused to the cholera toxin B subunit induces systemic and mucosal anti-amebic and anti-V. Cholerae antibody responses in mice
21. Coexpression of the B subunit of Shiga toxin 1 and EaeA from enterohemorrhagic Escherichia coli in Vibrio cholerae vaccine strains
22. Heterologous antigen expression in Vibrio cholerae vector strains
23. Expression of Shigella sonnei lipopolysaccharide in Vibrio cholerae
24. Development of Shigella sonnei live oral vaccines based on defined rfb Inaba deletion mutants of Vibrio cholerae expressing the Shigella serotype D O polysaccharide
25. Molecular cloning and characterization of the genetic determinants that express the complete Shigella serotype D (Shigella sonnei) lipopolysaccharide in heterologous live attenuated vaccine strains
26. In vivo expression and immunoadjuvancy of a mutant of heat-labile enterotoxin of Escherichia coli in vaccine and vector strains of Vibrio cholerae
27. Development of a ΔglnA balanced lethal plasmid system for expression of heterologous antigens by attenuated vaccine vector strains of Vibrio cholerae
28. In vitro and in vivo analyses of constitutive and in vivo-induced promoters in attenuated vaccine and vector strains of Vibrio cholerae
29. Development of a germfree mouse model of Vibrio cholerae infection
30. Optimizing the germfree mouse model for in vivo evaluation of oral Vibrio cholerae vaccine and vector strains
31. Development of a live, oral, attenuated vaccine against El Tor cholera
32. The induction of systemic and mucosal immune responses to antigen-adjuvant compositions administered into the skin: Alterations in the migratory properties of dendritic cells appears to be important for stimulating mucosal immunity